IL7Fc Armored CAR-T Cells for Solid Tumor Persistence and Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chimeric antigen receptor (CAR) T-cell therapies face challenges in treating solid tumors due to tumor antigen escape, immunosuppressive tumor microenvironments, and limited persistence and effectiveness, leading to relapse and toxicity issues.
Innovation Solution
Development of IL7Fc armored CAR-T cells that produce soluble homodimeric IL7 to enhance T-cell recruitment and activation, overcome immunosuppression, and improve persistence and penetration within the tumor microenvironment, while incorporating booster elements for enhanced cytotoxicity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cells are used to treat solid tumors, then T-cell activation and cytotoxicity are achieved, but tumor antigen escape and immunosuppressive microenvironment lead to limited persistence and relapse
Solution Approach 1:
The CAR-T cells are engineered to simultaneously perform multiple functions: (1) target tumor cells via CAR-mediated antigen recognition, (2) secrete IL-7 for T-cell survival and expansion, (3) secrete IL-15 for metabolic support and persistence, and (4) secrete IFN-γ for anti-tumor immunity. This multi-functional design enhances both persistence and adaptability against tumor escape mechanisms.
Solution Approach 2:
The patent creates a composite therapeutic agent by combining CAR-T cells with embedded cytokine production capabilities (IL-7, IL-15, IFN-γ). This composite structure allows the cells to function as both targeted killers and local cytokine factories, improving reliability and adaptability simultaneously.
2Power
If CAR-T cells are engineered with enhanced cytotoxicity, then anti-tumor activity increases, but toxicity and off-target effects worsen
Solution Approach 1:
The cytokine production (IL-7, IL-15, IFN-γ) is localized to the tumor microenvironment through CAR-mediated targeting. The cells concentrate their therapeutic effect at the tumor site while minimizing systemic exposure, thereby enhancing local cytotoxicity power while reducing generalized toxicity.
Solution Approach 2:
The cytokines IL-7 and IL-15 act as intermediaries that support T-cell survival and function locally at the tumor site, allowing enhanced cytotoxicity to be sustained without requiring high systemic doses that would cause off-target toxicity.
3Area of stationary object
If CAR-T cells are administered to treat solid tumors, then tumor targeting is achieved, but limited penetration and expansion within the tumor microenvironment reduce effectiveness
Solution Approach 1:
The CAR-T cells are engineered to self-produce IL-7 and IL-15, creating a local cytokine environment that promotes their own survival, expansion, and persistence within the tumor microenvironment. This self-service mechanism enables sustained productivity and broader tumor coverage without external support.
Solution Approach 2:
The cells pre-configure their cytokine production capability before entering the tumor microenvironment, allowing them to immediately establish a supportive local environment upon contact with tumor cells, facilitating rapid expansion and penetration without relying on external cytokine administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL7Fc armored CAR-T cells demonstrate improved surface expression, cytolysis, and persistence, enabling effective targeting and treatment of solid tumors by enhancing T-cell expansion and anti-tumor cytotoxicity, and reducing relapse.
Implementation Method 1
The IL7Fc armored CAR-T cells produce soluble homodimeric IL7 to recruit and activate more T cells and other immune cells from the host to attack tumor cells
Data Source
AI summary
Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.